Case Overview

The Parties

The Patent at Issue

The contested patent, **U.S. Patent No. 8,142,413 B2** (application no. US12/824734), covers a **coaxial guide catheter for interventional cardiology procedures** — a device used to deliver therapeutic tools, such as stents or balloons, to target sites within coronary or peripheral vasculature. Guide catheters are foundational components of percutaneous coronary intervention (PCI), making patent control over their design commercially and clinically significant.

• • US 8,142,413 B2 — Coaxial guide catheter technology for interventional cardiology

The Verdict & Legal Analysis

Outcome

The Federal Circuit **affirmed** the challenged patent’s validity, with the case basis of termination recorded as **”Patent Upheld.”** No damages figure was disclosed in the available case record, consistent with the appellate posture of a patentability/invalidity dispute rather than a damages proceeding. The affirmance means **U.S. Patent No. 8,142,413 B2 survives the validity challenge intact**, restoring or preserving Medtronic’s full enforcement rights over the claimed coaxial guide catheter technology.

Verdict Cause Analysis

The verdict cause is identified as **patentability — invalidity/cancellation action**, indicating Teleflex pursued a strategy of invalidating the Medtronic patent rather than contesting infringement on the merits. This is a common and tactically sound approach in medical device litigation, where invalidity can neutralize an infringement claim entirely without requiring design-around investment. Invalidity challenges before the Federal Circuit typically argue that asserted claims are anticipated by prior art (35 U.S.C. § 102) or would have been obvious to a person of ordinary skill in the art (35 U.S.C. § 103). Given the coaxial catheter’s functional complexity, claim construction of terms describing catheter geometry, coaxial configuration, and interventional application would have been central battlegrounds. The Federal Circuit’s affirmance indicates that Teleflex failed to meet the **clear and convincing evidence standard** required to invalidate an issued patent — a demanding burden that patent challengers frequently underestimate at the appellate stage. Specific claim construction positions, expert testimony details, and the precise invalidity theories advanced were not disclosed in the available case data.

Legal Significance

This decision carries meaningful precedential weight for **interventional cardiology patent litigation**. Federal Circuit affirmances of patent validity in device-specific technology areas reinforce the evidentiary difficulty of overcoming an issued patent’s presumption of validity on appeal. For patent practitioners, the case underscores that:

• • **Appellate invalidity challenges face steep odds** once validity has been upheld at a lower adjudicatory level.
• • **Coaxial catheter claim architecture** can withstand post-grant scrutiny when prosecution was well-conducted.
• • The CAFC continues to apply rigorous standards in medical device patent patentability disputes, offering predictability for both patent holders and challengers.